Phase I and phase II enzyme polymorphisms and childhood cancer

Journal of Investigative Medicine

Volumn 54, Issue 6, 2006, Pages 303-320

  Swinney, Ryan ^c   Hsu, Stephanie ^b   Tomlinson, Gail ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Hamon Center for Therapeutic Oncology Research   (United States)

^c University of Texas Southwestern Medical Center ^*

Author keywords

Acute lymphoblastic leukemia; Childhood cancer; Phase I enzymes; Phase II enzymes; Xenobiotic metabolizing enzymes

Indexed keywords

CARCINOGEN; CYTOCHROME; DRUG METABOLIZING ENZYME; ENZYME; OXIDOREDUCTASE; PHASE I ENZYME; PHASE II ENZYME; XENOBIOTIC AGENT; XENOBIOTIC METABOLIZING ENZYME;

ADOLESCENT; AMINO ACID SEQUENCE; CANCER RESEARCH; CANCER SUSCEPTIBILITY; CANCER THERAPY; CHILD; CHILDHOOD CANCER; CONJUGATION; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; ETHNOLOGY; HEREDITY; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEOMICS; REVIEW; TREATMENT OUTCOME;

EID: 33845599504     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2006.05062     Document Type: Review

References (139)

1. American Cancer Society. Cancer facts & figures 2005. Atlanta: American Cancer Society; 2005.
2. Stiller CA. Epidemiology and genetics of childhood cancer. Oncogene 2004;23:6429-44.
3. Pui CH, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003;290:2001-7.
4. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
5. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643-6.
6. Pakakasama S, Tomlinson GE. Genetic predisposition and screening in pediatric cancer. Pediatr Clin North Am 2002;49:1393-413.
7. Krajinovic M, Labuda D, Sinnett D. Glutathione S-transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics 2002;12:655-8.
8. Krajinovic M, Sinnett H, Richer C, et al. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 2002;97:230-6.
9. Canalle R, Burim RV, Tone LG, Takahashi CS. Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen 2004;43:100-9.
10. Sheweita SA. Drug-metabolizing enzymes: mechanisms and functions. Curr Drug Metab 2000;1:107-32.
11. Hirvonen A. Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer. Environ Health Perspect 1999;107 Suppl 1:37-47.
12. Autrup H. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 2000;464:65-76.
13. Pelkonen O, Raunio H, Rautio A, Lang M. Xenobiotic-metabolizing enzymes and cancer risk: correspondence between genotype and phenotype. IARC Sci Publ 1999;148:77-88.
14. Williams JA, Phillips DH. Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 2000;60:4667-77.
15. Kiyohara C. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer. J Epidemiol 2000;10:349-60.
16. Antognelli C, Mearini L, Talesa VN, et al. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005;63:240-51.
17. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 1994;102 Suppl 9:55-61.
18. Linder MW, Valdes R Jr. Genetic mechanisms for variability in drug response and toxicity. J Anal Toxicol 2001;25:405-13.
19. Chacko P, Joseph T, Mathew BS, et al. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. Mutat Res 2005;581:153-63.
20. Ishibe N, Wiencke JK, Zuo ZF, et al. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiol Biomarkers Prev 1997;6:1075-80.
21. Sheweita SA, Tilmisany AK. Cancer and phase II drug-metabolizing enzymes. Curr Drug Metab 2003;4:45-58.
22. Sinnett D, Krajinovic M, Labuda D. Genetic susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma 2000;38:447-62.
23. Krajinovic M, Labuda D, Richer C, et al. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999;93:1496-501.
24. Lemos MC, Cabrita FJ, Silva HA, et al. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999;20:1225-9.
25. Infante-Rivard C, Labuda D, Krajinovic M, Sinnett D. Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms. Epidemiology 1999;10:481-7.
26. Krajinovic M, Labuda D, Mathonnet G, et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002;8:802-10.
27. Sheweita SA. Drug-metabolizing enzymes: mechanisms and functions. Curr Drug Metab 2000;1:107-32.
28. Qin G, Meng Z. Effect of sulfur dioxide inhalation on CYP1A1 and CYP1A2 in rat liver and lung. Toxicol Lett 2005;160:34-42.
29. Crofts F, Taioli E, Trachman J, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994;15:2961-3.
30. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding regions of the human cytochrome P450IA1 gene. J Biochem 1991;110:407-11.
31. Kellermann G, Shaw CR, Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 1973;289:934-7.
32. Vineis P, Veglia F, Anttila S, et al. CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions. Biomarkers 2004;9:298-305.
33. Kawajiri K, Nakachi K, Imai K, et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990;263:131-3.
34. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem (Tokyo) 1991;110:407-11.
35. Kawajiri K, Nakachi K, Imai K, et al. The CYP1A1 gene and cancer susceptibility. Grit Rev Oncol Hematol 1993;14:77-87.
36. Xu X, Kelsey KT, Wiencke JK, et al. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1996;5:687-92.
37. Tefre T, Ryberg D, Haugen A, et al. Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991;1:20-5.
38. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, et al. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1992;1:485-9.
39. Oesch-Bartlomowicz B, Oesch F. Cytochrome-P450 phosphorylation as a functional switch. Arch Arch Biochem Biophys 2003;409:228-34.
40. Hanoika N, Tanaka-Kagawa T, Miyata Y, et al. Functional characterization of three human cytochrome P450 2E1 variants with amino acid substitutions. Xenobiotica 2003;33:575-86.
41. Miksys S, Tyndale RF. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 2004;36:313-33.
42. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III anti-arrhythmic drugs. Drug Saf 2003;26:421-38.
43. Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35:35-98.
44. Lotsch J, Skarke C, Tegeder I, Geisslinger G. Drug interactions with patient-controlled analgesia. Clin Pharmacokinet 2002;41:31-57.
45. Wenk M, Todesco L, Krähenbühl S. Effect of St. John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyl-transferase 2, and xanthine oxidase on healthy males and females. Br J Clin Pharmacol 2004;57:495-9.
46. Gurley BJ, Gardner SF, Hubbard MA, et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005;22:525-39.
47. van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005;23:513-22.
48. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
49. Leathart JB, London SJ, Steward A, et al. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998;8:529-41.
50. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003;17:27-41.
51. Raimundo S, Fischer J, Eichelbaum M, et al. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000;10:577-81.
52. Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001;11:573-85.
53. Lovlie R, Daly AK, Matre GE, et al. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultra-rapid metabolism? Pharmacogenetics 2001;11:45-55.
54. Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-58.
55. van Schaik RHN, Teuling E, Meijer M, et al. CYP2C19 genotype predicts duration of response to tamoxifen in advanced breast cancer. Clin Pharmacol Ther 2005;77:P23(PI-56).
56. Ozawa S, Soyama A, Saeki M, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004;19:83-95.
57. Wan Y-J, Poland RE, Han G, et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 2001;11:489-99.
58. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229-43.
59. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
60. Oscarson M, Hidestrand M, Johansson I, et al. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 1997;52:1034-40.
61. Joseph T, Kusumakumary P, Chacko P, et al. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1, AND GSTT1 and susceptibility to acute lymphoblastic leukemia in Indian children. Pediatr Blood Cancer 2004;43:560-7.
62. Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol 2004;160:825-41.
63. Dhaini HR, Thomas DG, Giordano TJ, et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 2003;21:2481-5.
64. Yokose T, Doy M, Taniguchi T, et al. Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues. Virchows Arch 1999;434:401-11.
65. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 1998;95:13176-81.
66. Collado M, Barragan E, Bolufer P, et al. Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. Leuk Res 2005;29:595-7.
67. Blanco JG, Edick MJ, Hancock ML, et al. Genetic polymorphisms in CYP3A4, CYP3A5, and NQO1 in children who developed therapy-related myeloid malignancies. Pharmaco-genetics 2002;12:605-11.
68. Den Boer ML, Pieters R, Kazemier KM, et al. Different expression of glutathione S-transferase α, μ, and π in childhood acute lymphoblastic and myeloid leukemia. Br J Haematol 1999;104:321-7.
69. Nebert DW, Vailiou V. Analysis of the glutathione S-transferase (GST) gene family. Hum Genomics 2004;1:460-4.
70. Pari FF. Glutathione S-transferase genotypes and cancer risk. Cancer Lett 2005;221:123-9.
71. Vineis P. The relationship between polymorphisms of xenobiotic metabolizing enzymes and susceptibility to cancer. Toxicology 2002;181-2:457-62.
72. Drummond SN, Gomez RS, Noronha JCM, et al. Association between GSTT-1 gene deletion and the susceptibility to oral squamous cell carcinoma in cigarette-smoking subjects. Oral Oncol 2005;41:515-9.
73. Tuimala J, Szekely G, Wikman H, et al. Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: effects on levels of sister chromatid exchanges and chromosomal aberrations. Mutat Res 2004;554:319-33.
74. Norppa H. Genetic susceptibility, biomarker response, and cancer. Mutat Res 2003;544:339-48.
75. Hall AG, Autzen P, Cattan AR, et al. Expression of μ class glutathione S-transferase correlates with event-free survival in childhood acute lymphoblastic leukemia. Cancer Res 1994;54:5251-4.
76. Barnette P, Scholl R, Blandford M, et al. High throughput detection of glutathione S-transferase polymorphic alleles in a pediatric cancer population. Cancer Epidemiol Biomarkers Prev 2004;13:304-13.
77. Davies SM, Bhatia S, Ross JA, et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 2002;100:67-71.
78. Anttila S, Hirvonen A, Vainio H, et al. Immunohistochemical localization of glutathione S-transferases in human lung. Cancer Res 1993;53:5643-8.
79. Kearns PR, Chrzanowska-Lightowlers ZM, Pieters R, et al. Mu class glutathione S-transferase mRNA isoform expression in acute lymphoblastic leukemia. Br J Haematol 2003;120:80-8.
80. Lanciotti M, Coco S, Di Michele P, et al. Glutathione S-transferase polymorphisms and susceptibility to neuroblastoma. Pharmacogenet Genomics 2005;15:423-6.
81. Hall AG, McGuckin AG, Pearson AD, et al. Glutathione S-transferase in bone marrow metastases of disseminated neuroblastoma. J Clin Pathol 1994;47:468-9.
82. Bourhis J, Hartmann O, Riou G, et al. Expression of MDR1 and GST-π genes and tumor response in 35 advanced neuroblastomas. Proc Annu Meet ASCO 1990;9:PA1136.
83. Meissner B, Stanulla M, Ludwig W-D, et al. The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia. Leukemia 2004;18:1920-3.
84. Chen C-L, Liu Q, Pui C-H, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997;89:1701-7.
85. Infante-Rivard C, Amre D, Sinnett D. GSTT1 and CYP2E1 polymorphisms and trihalomethanes in drinking water: effect on childhood leukemia. Environ Health Perspect 2002;110:591-3.
86. Mitchell KR, Warshawsky D. Xenobiotic inducible regions of the human arylamine N-acetyltransferase 1 and 2 genes. Toxicol Lett 2003;139:11-23.
87. Dupret JM, Rodrigues-Lima F. Structure and regulation of the drug-metabolizing enzymes arylamine N-acetyltransferases. Curr Med Chem 2005;12:311-8.
88. Fretland AJ, Doll MA, Leff MA, Hein DW. Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. Pharmacogenetics 2001;11:511-20.
89. Krajinovic M, Richer C, Sinnett H, et al. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 2000;9:557-62.
90. Smelt VA, Mardon HJ, Sim E. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2. Pharmacol Toxicol 1998;83:149-57.
91. Derewlany LO, Knie B, Koren G. Arylamine N-acetyltransferase activity of the human placenta. J Pharmacol Exp Ther 1994;269:756-60.
92. Pacifici GM, Bencini C, Rane A. Acetyltransferase in humans: development and tissue distribution. Pharmacology 1986;32:283-91.
93. Hein DW. N-Acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis. Toxicol Lett 2000;112-3:349-56.
94. Smith MT. Benzene, NQO1, and genetic susceptibility to cancer. Proc Natl Acad Sci U S A 1999;96:7624-6.
95. Siegel D, Gustafson DL, Dehn DL, et al. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004;65:1238-47.
96. Iskander K, Jaiswal AK. Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem Biol Interact 2005;153-4:147-57.
97. Tsvetkov P, Asher G, Reiss V, et al. Inhibition of NAD(P)H:-quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci U S A 2005;102:5535-40.
98. Siemankowski LM, Morreale J, Butts BD, Briehl MM. Increased tumor necrosis factor-alpha sensitivity of MCF-7 cells transfected with NAD(P)H:quinone reductase. Cancer Res 2000;60:3638-44.
99. Asher G, Lotem J, Kama R, et al. NQO0 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A 2002;99:3099-104.
100. Saldivar SJ, Wang Y, Zhao H, et al. An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutat Res 2005;582:71-8.
101. Lanciotti M, Dufour C, Corral L, et al. Genetic polymorphism of NAD(P)H:quinine odixoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia 2005;19:214-6.
102. Sirma S, Agaoglu L, Yildiz I, et al. NAD(P)H:quinine oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia. Pediatr Blood Cancer 2004;43:568-70.
103. Smith MT, Wang Y, Skibola CF, et al. Low NAD(P)H:quinine oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 2002;100:4590-3.
104. Nebert DW, Roe AL, Vandale SE, et al. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 2002;4:62-70.
105. Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 1997;76:852-4.
106. Kracht T, Schrappe M, Strehl S, et al. NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms. Haematologica 2004;89:1492-7.
107. Powell JE, Parkes SE, Cameron AH, Mann JR. Is the risk of cancer increased in Asians living in the UK? Arch Dis Child 1994;71:398-403.
108. Cummins C, Winter H, Marie R, et al. Childhood cancer in the south Asian population of England (1990-1992). Br J Cancer 2001;84:1215-8.
109. Wilkinson JD, Fleming LE, MacKinnon J, et al. Lymphoma and lymphoid leukemia incidence in Florida children: ethnic and racial distribution. Cancer 2001;91:1402-8.
110. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 1995;5:199-206.
111. Kelly KM, Perentesis JP, Children's Oncology Group. Poly-morphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. Ann Oncol 2002;13 Suppl 1:34-9.
112. Wiemels JL, Pagnamenta A, Taylor GM, et al, the United Kingdom Childhood Cancer Study Investigators. A lack of function NAD(P)H:quinine oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res 1999;59:4095-9.
113. Delongchamp RR, Mabuchi K, Yoshimoto Y, Preston DL. Cancer mortality among atomic bomb survivors exposed in utero or as young children, October 1950-May 1992. Radiat Res 1997;147:385-95.
114. Infante-Rivard C, Krajinovic M, Labuda D, Sinnett D. Parental smoking, CYP1A1 genetic polymorphisms and childhood leukemia (Quebec, Canada). Cancer Causes Control 2000;11:547-53.
115. Kusafuka T, Fukuzawa M, Oue T, et al. Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr Surg 1997;32:1175-80.
116. McNeil DE, Cote TR, Clegg L, Mauer A. SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol 2002;39:554-7; discussion 552-3.
117. Wrensch MR, Miike R, Sison JD, et al. CYP1A1 variants and smoking-related lung cancer in San Francisco Bay area Latinos and African Americans. Int J Cancer 2005;113:141-7.
118. Hagiwara T, Kono S, Yin G, et al. Genetic polymorphism in cytochrome P450 7A1 and risk of colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Res 2005;65:2979-82.
119. Balta G, Yuksek N, Ozyurek E, et al. Characterization of MTHFR, GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes in childhood acute leukemia. Am J Hematol 2003;73:154-60.
120. Autrup H. Genetic polymorphisms in human xenobiotic metabolizing enzymes as susceptibility factors in toxic response. Mutat Res 2000;464:65-76.
121. Hukkanen J, Pelkonen O, Raunio H. Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: possible role in susceptibility for ILD. Eur Respir J Suppl 2001;32:122s-6s.
122. Brockmoller J, Cascorbi I, Kerb R, et al. Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicol Lett 1998;102-103:173-83.
123. Gallou C, Longuemaux S, Deloménie C, et al. Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumor suppressor gene transversions in sporadic renal cell carcinoma. Pharmacogenetics 2001;11:521-35.
124. Longuemaux S, Delomenie C, Gallou C, et al. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res 1999;59:2903-8.
125. Wu MT, Wang YT, Ho CK, et al. SULT1A1 polymorphism and esophageal cancer in males. Int J Cancer 2003;103:101-4.
126. Wang Y, Spitz MR, Tsou AM, et al. Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer 2002;35:137-42.
127. Ozawa S, Katoh T, Inatomi H, et al. Association of genotypes of carcinogen-activating enzymes, phenol Sulfotransferase SULT1A1 (ST1A3) and arylamine N-acetyltransferase NAT2, with urothelial cancer in a Japanese population. Int J Cancer 2002;102:418-21.
128. Glatt H, Meinl W. Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch Pharmacol 2004;369:55-68.
129. Ahmad N, Mukhtar H. Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol 2004;123:417-25.
130. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features and quality of life. Ann Rheum Dis 2005;64:ii18-23.
131. Smith G, Dawe RS, Clark C, et al. Quantitative real-time reverse transcription-polymerase chain reaction analysis of drug metabolizing and cytoprotective genes in psoriasis and regulation by ultraviolet radiation. J Invest Dermatol 2003;121:390-8.
132. Smith G, Wolf CR, Deeni YY, et al. Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases. Lancet 2003;361:1336-43.
133. Reich K, Westphal G, Schulz T, et al. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol 1999;113:214-20.
134. Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002;162:405-12.
135. Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004;4:151-60.
136. Alonso-Aperte E, Varela-Moreiras G. Drugs-nutrient interactions: a potential problem during adolescence. Eur J Clin Nutr 2000;54 Suppl 1:869-74.
137. Zhu BT. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002;3:321-49.
138. Bhuvaneswari V, Abraham SK, Nagini S. Combinatorial antigenotoxic and anticarcinogenic effects of tomato and garlic through modulation of xenobiotic-metabolizing enzymes during hamster buccal pouch carcinogenesis. Nutrition 2005;21:726-31.
139. Ingelman-Sundberg M. Functional consequences of polymorphism of xenobiotic metabolising enzymes. Toxicol Lett 1998;102-3:155-60.